Investigation Report on China Leuprorelin Market, 2010-2019

Originally developed by Takeda Pharmaceutical Co., Ltd, leuprorelin is a polypeptide used to treat prostate cancer and so on
Reference: 1508300
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
8/18/2015
Pages
30
Version:
2010
Charts:
30
Language
  • English
  • Chinese
Format
License

Description
Originally developed by Takeda Pharmaceutical Co., Ltd, leuprorelin is a polypeptide used to treat prostate cancer and so on. Leuprorelin can inhibit pituitary gland and release gonadotropin Leuprolide acts as an agonist at pituitary GnRH receptors, leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes.
Having been marketed in 1994 for the first time, leuprorelin entered China under the trade name of enantone in 2000. As it is the specific drug for such sex hormone-related diseases as prostate cancer and endometriosis, it grows fast in China. Due to the technology involved in production of polypeptide, there was no generic drug for a long time despite its lack of patent protection in China. Currently, only generic drugs of Beijing Biote and Livzon are approved.
Leuprorelin develops fast after entering China with sales value in sample hospitals rising from about CNY 20 million in 2005 to over CNY 260 million in 2014 and CAGR during the period of 2006-2010 reaching 37%. Leuprorelin enjoys a vast demand in China. And Livzon, Beijing Biote Pharmaceutical Co., Ltd and Takeda Pharmaceutical Co., Ltd (Japan) occupy the market, among which Takeda Pharmaceutical Co., Ltd (Japan) had the largest market share of nearly 60% for sales value in 2014.
Due to unreliable heat of diet, Chinese children report increasingly obvious symptoms of sexual precocity, which is bad for their healthy development and attracts more and more parents' attention. In recent years, such problems as female fibroid caused by abnormal secretion of hypophyseal hormone have become increasingly prominent. As these problems are increasingly emphasized, leuprorelin which regulates the secretion of gonadotropins will enjoy a vast market. Since Lee's Pharmaceutical Holdings Limited is now the only company which applied to produce generic drugs of leuprorelin, there are still opportunities for future generic drugs.

Readers can get at least the following information through this report:
-market size of leuprorelin in China
-competitive landscape of leuprorelin market in China
-price of leuprorelin made by different enterprises in China
-market outlook of leuprorelin in China

The author suggests the following groups of people purchase this report:
- manufacturers of polypeptide drugs
-investors/research institutions interested in Chinese medicine market
--any interest in Chinese medicine market, please contact CRI for customized survey service


Table of Contents

1 Related Concepts of Leuprorelin
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Leuprorelin in China
2.1 Patent Status and Approval Information of Leuprorelin in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Leuprorelin Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Leuprorelin Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Leuprorelin in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Leuprorelin in Chinese Hospitals in 2014
6.1 Shanghai Livzon Pharmaceutical Co., Ltd.
6.2 Beijing Biote Pharmaceutical Co., Ltd
6.3 Takeda Pharmaceutical Co., Ltd (Japan)

7 Major Manufacturers of Leuprorelin in Chinese Market
7.1 Shanghai Livzon Pharmaceutical Co., Ltd.
7.2 Beijing Biote Pharmaceutical Co., Ltd
7.3 Takeda Pharmaceutical Co., Ltd (Japan)

8 Market Outlook of Leuprorelin in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts

Chart Patent Information of Leuprorelin in China
Chart Approval Information of Leuprorelin in China
Chart Leuprorelin Sales in China
Chart Sales Value of Leuprorelin in China
Chart Sales Value of Leuprorelin in Some Regions in China, 2010-2014
Chart Sales Volume of Leuprorelin in China, 2010-2014
Chart Sales Volume of Leuprorelin in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Leuprorelin Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Leuprorelin Made by Livzon in China, 2010-2014
Chart Sales Value and Market Share of Leuprorelin Made by Beijing Biote in China, 2010-2014
Chart Sales Value and Market Share of Leuprorelin Made by Takeda (Japan) in China, 2010-2014
Chart Price of Leuprorelin Made by Livzon in Some Chinese Cities in 2014
Chart Price of Leuprorelin Made by Beijing Biote Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Leuprorelin Made by Takeda Pharmaceutical Co., Ltd (Japan) in Some Chinese Cities in 2014
Scroll